Morag McGreevey

Featured in: Favicon

lexology.com Favicon

mondaq.com Favicon

investingnews.com

Articles

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

Dec 10, 2024 | investingnews.com | Morag McGreevey

"Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease.
BLINCYTO® ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA | INN

Dec 7, 2024 | investingnews.com | Morag McGreevey

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2. 2 Percentage Points at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions THOUSAND OAKS, Calif. , Nov.
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

Dec 5, 2024 | investingnews.com | Yallalong Antimony |Morag McGreevey

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2. 2 Percentage Points at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions THOUSAND OAKS, Calif. , Nov.
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

Dec 2, 2024 | investingnews.com | Morag McGreevey

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2. 2 Percentage Points at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions THOUSAND OAKS, Calif. , Nov.
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

Nov 29, 2024 | investingnews.com | Morag McGreevey

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2. 2 Percentage Points at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions THOUSAND OAKS, Calif. , Nov.
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

Nov 26, 2024 | investingnews.com | Morag McGreevey |Melissa Pistilli

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2. 2 Percentage Points at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions THOUSAND OAKS, Calif. , Nov.
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Nov 20, 2024 | investingnews.com | Morag McGreevey |Melissa Pistilli |Diana Fernandez |Diana Fernández

Howard Chang , M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

Nov 14, 2024 | investingnews.com | Morag McGreevey |Lauren Kelly |Meagen Seatter

MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA ® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA ® Infusion Time Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C. Nov. 14-19, 2024 .
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

Nov 13, 2024 | investingnews.com | Morag McGreevey |Meagen Seatter

WAYPOINT was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of TEZSPIRE administered subcutaneously in adults with severe CRSwNP. Participants in the trial were symptomatic despite treatment with standard of care, intranasal corticosteroids (INCS).
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

Nov 8, 2024 | investingnews.com | Morag McGreevey |Meagen Seatter

Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday Nov. 13, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.